Korea's Celltrion Gains Foothold in Europe; Wins Clinical Trial Approval from Latvia For Herceptin Biosimilar
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Celltrion has secured an approval from EU member Latvia to perform clinical trials for its Herceptin (trastuzumab) biosimilar as part of its effort to prepare for the expiration of Roche's patent rights on the product in 2019 in Europe and the U.S
You may also be interested in...
Shocker For MNCs: India Steps Closer To Granting Compulsory Licenses On Herceptin, Sprycel, Ixempra
Buckling under pressure from domestic drug makers and patient groups, India readies to grant compulsory licenses for three key cancer drugs.
Shocker For MNCs: India Steps Closer To Granting Compulsory Licenses On Herceptin, Sprycel, Ixempra
Buckling under pressure from domestic drug makers and patient groups, India readies to grant compulsory licenses for three key cancer drugs.
Korean Government Shifts Attention To CRO Sector In Steady Drive To Build Up Biotech Infrastructure, Biosimilars
SEOUL - After realizing that it was a late comer, the Korean government is now moving to strengthen its local CRO industry to support a clinical trial infrastructure that is bursting at the seams as MNCs flock to Korea to conduct early-stage trials